Savara/SVRA

$4.48

-5.08%
-
1D1W1MYTD1YMAX

About Savara

Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Ticker

SVRA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Matthew Pauls

Employees

37

Headquarters

Austin, United States

Savara Metrics

BasicAdvanced
$667M
Market cap
-
P/E ratio
-$0.38
EPS
0.73
Beta
-
Dividend rate
$667M
0.73174
$5.70
$2.16
881K
14.902
21.677
21.677
-44.84%
-58.59%
-47.26%
5.477
6.004
-45.48%

What the Analysts think about Savara

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
96.21% upside
High $16.00
Low $6.00
$4.48
Current price
$8.79
Average price target

Savara Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$20M
26.88%
Profit margin
0%
NaN%

Savara Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 13.6%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.10
-$0.09
-$0.11
-
Expected
-$0.08
-$0.07
-$0.10
-$0.10
-$0.11
Surprise
-9.68%
38.89%
-13.18%
13.6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Savara stock?

Savara (SVRA) has a market cap of $667M as of May 18, 2024.

What is the P/E ratio for Savara stock?

The price to earnings (P/E) ratio for Savara (SVRA) stock is 0 as of May 18, 2024.

Does Savara stock pay dividends?

No, Savara (SVRA) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Savara dividend payment date?

Savara (SVRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Savara?

Savara (SVRA) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Savara stock price target?

The target price for Savara (SVRA) stock is $8.79, which is 96.21% above the current price of $4.48. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Savara stock

Buy or sell Savara stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing